Logo image of NVAX

NOVAVAX INC (NVAX) Stock Fundamental Analysis

NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD

6.67  -0.4 (-5.66%)

After market: 6.61 -0.06 (-0.9%)

Fundamental Rating

2

Overall NVAX gets a fundamental rating of 2 out of 10. We evaluated NVAX against 567 industry peers in the Biotechnology industry. NVAX may be in some trouble as it scores bad on both profitability and health. NVAX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year NVAX has reported negative net income.
NVAX had a negative operating cash flow in the past year.
NVAX had negative earnings in each of the past 5 years.
NVAX had negative operating cash flow in 4 of the past 5 years.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

The Return On Assets of NVAX (-12.02%) is better than 85.04% of its industry peers.
Industry RankSector Rank
ROA -12.02%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

Looking at the Gross Margin, with a value of 70.35%, NVAX belongs to the top of the industry, outperforming 81.87% of the companies in the same industry.
NVAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVAX has more shares outstanding
Compared to 5 years ago, NVAX has more shares outstanding
Compared to 1 year ago, NVAX has a worse debt to assets ratio.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

NVAX has an Altman-Z score of -4.27. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.27, NVAX perfoms like the industry average, outperforming 42.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.27
ROIC/WACCN/A
WACC10.83%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

NVAX has a Current Ratio of 0.98. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
NVAX has a worse Current ratio (0.98) than 88.73% of its industry peers.
A Quick Ratio of 0.97 indicates that NVAX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.97, NVAX is doing worse than 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.97
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.16% over the past year.
NVAX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.66%.
Measured over the past years, NVAX shows a very strong growth in Revenue. The Revenue has been growing by 105.31% on average per year.
EPS 1Y (TTM)70.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.36%
Revenue 1Y (TTM)-30.66%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-69.69%

3.2 Future

Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.82% on average per year.
The Revenue is expected to decrease by -8.27% on average over the next years.
EPS Next Y147.91%
EPS Next 2Y48.87%
EPS Next 3Y25.05%
EPS Next 5Y19.82%
Revenue Next Year-1.31%
Revenue Next 2Y-12.2%
Revenue Next 3Y-22.56%
Revenue Next 5Y-8.27%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.44, the valuation of NVAX can be described as reasonable.
97.54% of the companies in the same industry are more expensive than NVAX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of NVAX to the average of the S&P500 Index (21.38), we can say NVAX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.44
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NVAX's earnings are expected to grow with 25.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.87%
EPS Next 3Y25.05%

More info and screens

0

5. Dividend

5.1 Amount

NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVAVAX INC

NASDAQ:NVAX (4/25/2025, 8:00:01 PM)

After market: 6.61 -0.06 (-0.9%)

6.67

-0.4 (-5.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-07 2025-05-07
Inst Owners60.5%
Inst Owner Change-0.17%
Ins Owners0.35%
Ins Owner Change22.03%
Market Cap1.07B
Analysts78.46
Price Target17.68 (165.07%)
Short Float %25.14%
Short Ratio6.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.2%
Min EPS beat(2)-58.31%
Max EPS beat(2)5.92%
EPS beat(4)2
Avg EPS beat(4)-22.47%
Min EPS beat(4)-58.31%
Max EPS beat(4)5.92%
EPS beat(8)5
Avg EPS beat(8)-15.97%
EPS beat(12)5
Avg EPS beat(12)-60.69%
EPS beat(16)6
Avg EPS beat(16)-78.5%
Revenue beat(2)2
Avg Revenue beat(2)7.47%
Min Revenue beat(2)2.61%
Max Revenue beat(2)12.33%
Revenue beat(4)2
Avg Revenue beat(4)-1.32%
Min Revenue beat(4)-11.17%
Max Revenue beat(4)12.33%
Revenue beat(8)4
Avg Revenue beat(8)7.96%
Revenue beat(12)5
Avg Revenue beat(12)-1.87%
Revenue beat(16)6
Avg Revenue beat(16)-2.6%
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)143.47%
EPS NQ rev (3m)138.37%
EPS NY rev (1m)43.52%
EPS NY rev (3m)830.04%
Revenue NQ rev (1m)184.36%
Revenue NQ rev (3m)329.64%
Revenue NY rev (1m)39.91%
Revenue NY rev (3m)21.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.44
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)0.79
Fwd EY11.85%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS4.24
BVpS-3.88
TBVpS-4.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.35%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.92%
Cap/Sales 1.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.97
Altman-Z -4.27
F-Score4
WACC10.83%
ROIC/WACCN/A
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.36%
EPS Next Y147.91%
EPS Next 2Y48.87%
EPS Next 3Y25.05%
EPS Next 5Y19.82%
Revenue 1Y (TTM)-30.66%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-69.69%
Revenue Next Year-1.31%
Revenue Next 2Y-12.2%
Revenue Next 3Y-22.56%
Revenue Next 5Y-8.27%
EBIT growth 1Y56.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.57%
EBIT Next 3Y13.97%
EBIT Next 5YN/A
FCF growth 1Y86.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.78%
OCF growth 3YN/A
OCF growth 5YN/A